Skip to content ↓

Arts News

The Lyric Opera of Chicago's recent staging of Professor John Harbison's opera The Great Gatsby has received positive reviews. "Watching Lyric's tightly paced, beautifully polished production, it was clear that Harbison's Gatsby is, at its core, an intimate tale," wrote Wynne Delacoma in the Chicago Sun-Times. "If we surrender our expectations for grand scale and follow Harbison into its moody, quiet heart, we will find an atmospheric universe where hopes and disappointments are as piercing yet evanescent as the coastal fog off Long Island." John von Rhein of the Chicago Tribune said that "Harbison, working from his own ingenious libretto, has met the challenge with great flair, creating not a pale imitation of the novel but a worthy, independent work of art." Revisiting the work, Richard Dyer of the Boston Globe noted that the piece "may be the most musically sophisticated opera ever written by an American composer, and some of the score haunts the memory and the imagination.'' New York City's Metropolitan Opera -- which commissioned the opera -- plans a restaging in spring 2002.

--------------------------------

Vladimir V. Zelevinsky may no longer be the arts editor of The Tech, but that doesn't mean he's retired from journalism. The physics alumnus (SB 1994, SM 1998) has reappeared in print -- as a correspondent reviewing theater and movies for the Boston Globe.

A version of this article appeared in MIT Tech Talk on November 8, 2000.

Related Topics

More MIT News

Rich Nielsen, Volha Charnysh, Kevin Dorst, and Emily Richmond Pollock seated at a table, talking

Building a scholarly community

The SHASS Faculty Fellows Program, administered by the MIT Human Insight Collaborative, is fostering new research projects and creating space for supportive and interdisciplinary discussion.

Read full story

Globular blue and white orbs "examining" single-stranded RNA products and marking them with green checks or red x's

Why are some bacterial genes high in purines?

In certain species of bacteria, the answer lies in shielding RNA transcripts from a quality-control factor called Rho. Understanding the requirements for expressible sequences is critical for expression engineering of therapeutic agents.

Read full story